Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Ophthalmic Vis Res ; 17(4): 505-514, 2022.
Article in English | MEDLINE | ID: mdl-36620706

ABSTRACT

Purpose: Presence of diabetes in glaucoma patients may influence findings while documenting the progression of glaucoma. We conducted the study to compare individual and combined effects of diabetes and glaucoma on macular thickness and ganglion cell complex thickness. Methods: The present study is a cross-sectional analysis of 172 eyes of 114 individuals. The groups were categorized according to the following conditions: glaucoma, diabetes mellitus, both glaucoma and diabetes (`both' group), and none of these conditions (`none' group). Patients with diabetes did not have diabetic retinopathy (DR). We compared retinal nerve fiber layer (RNFL) thickness, ganglion cell complex (GCC) thickness, foveal loss of volume (FLV), and global loss of volume (GLV) among the groups. We used random effects multivariate analysis to adjust for potential confounders. Results: The mean (SD) age of these individuals was 60.7 (10.1) years. The total average RNFL and GCC were significantly lower in the glaucoma group (RNFL: -36.27, 95% confidence intervals [CI]: -42.79 to -29.74; P < 0.05, and GCC: -26.24, 95% CI: -31.49 to -20.98; P < 0.05) and the `both' group (RNFL: -24.74, 95% CI: -32.84 to -16.63; P < 0.05, and GCC: -17.92, 95% CI: -24.58 to -11.26; P < 0.05) as compared with the `none' group. There were no significant differences in the average RNFL values and total average GCC between the diabetes group and the `none' group. The values of FLV and GLV were significantly higher in the `glaucoma' group and the `both' group as compared with the `none' group. The foveal values were not significantly different across these four groups. Among the glaucoma cases, 25% were mild, 30% were moderate, and 45% were severe; there was no significant difference in the proportion of severity of glaucoma between the `glaucoma only' and `both' groups (p=0.32). After adjusting for severity and type of glaucoma, there were no statistically significant differences in the values of average RNFL (6.6, 95% CI: -1.9 to 15.2; P=0.13), total average GCC (3.6, -95% CI: -2.4 to 9.6; P=0.24), and GLV (-3.9, 95% CI: -9.5 to 1.6; P=0.16) in the `both group' as compared with the glaucoma only group. Conclusion: We found that diabetes with no DR did not significantly affect the retinal parameters in patients with glaucoma. Thus, it is less likely that thickness of these parameters will be overestimated in patients with glaucoma who have concurrent diabetes without retinopathy.

2.
Indian J Ophthalmol ; 69(5): 1322-1325, 2021 May.
Article in English | MEDLINE | ID: mdl-33913891

ABSTRACT

The novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, has challenged the medical community. Several ocular manifestations secondary to COVID-19 have been documented. Prolonged hospitalization exposes the patient to various multiresistant bacteria making them prone to various secondary infections. This case series describes four cases of presumed fungal endogenous endophthalmitis in patients who recovered from COVID-19.


Subject(s)
COVID-19 , Coinfection , Endophthalmitis , Eye Infections, Fungal , Endophthalmitis/diagnosis , Endophthalmitis/etiology , Eye Infections, Fungal/diagnosis , Humans , SARS-CoV-2
3.
J Glaucoma ; 25(8): 674-80, 2016 08.
Article in English | MEDLINE | ID: mdl-26967258

ABSTRACT

PURPOSE: To analyse the prevalence, incidence, and risk factors of glaucoma in Vogt Koyanagi Harada (VKH) disease and study the changes in visual acuity and intraocular pressure (IOP) with treatment. MATERIALS AND METHODS: Retrospective chart analysis of 448 eyes of 224 patients of Indian origin diagnosed with VKH disease from January 1990 to December 2013, who had a minimum follow-up of 3 months was performed. RESULTS: Seventy-one eyes (15.8%) developed sustained elevation in IOP. The prevalence of glaucoma at presentation was 15.8% and the cumulative incidence of glaucoma was 11.7%. The mechanisms of glaucoma were open-angle glaucoma in 46 eyes, (64.8%), angle closure in 21 eyes (29.6%), and of combined mechanisms in the remainder (4 eyes, 5.6%). Acute angle-closure crisis developed in 9 eyes (12.6%). Uveal effusion (odds ratio 9.47; confidence interval, 4.08-20.03) and increased number of recurrences (odds ratio 1.31; confidence interval, 1.13-1.53) were found to be significant risk factors for the development of glaucoma. Successful control of IOP was achieved in 64% at 12 months using medical/ laser treatment for glaucoma and was 50 % at 12 months following surgical management. CONCLUSIONS: Glaucoma is a frequent complication of uveitis in VKH disease. Presence of uveal effusion and increased number of recurrences of inflammation are significant risk factors.


Subject(s)
Glaucoma/epidemiology , Glaucoma/etiology , Uveomeningoencephalitic Syndrome/complications , Adult , Aged , Antihypertensive Agents/therapeutic use , Carbonic Anhydrase Inhibitors/therapeutic use , Female , Glaucoma/therapy , Humans , Incidence , Intraocular Pressure , Iridectomy , Male , Middle Aged , Odds Ratio , Prevalence , Recurrence , Retrospective Studies , Risk Factors , Trabeculectomy , Uveitis/etiology , Visual Acuity
4.
Indian J Ophthalmol ; 62(10): 985-91, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25449931

ABSTRACT

Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. It is called the great masquerader owing to its varied clinical presentations. Very often, a patient of MG may present to the ophthalmologist given that a large proportion of patients with systemic myasthenia have ocular involvement either at presentation or during the later course of the disease. The treatment of ocular MG involves both the neurologist and ophthalmologist. Thus, the aim of this review was to highlight the current diagnosis, investigations, and treatment of ocular MG.


Subject(s)
Disease Management , Myasthenia Gravis , Global Health , Humans , Morbidity , Myasthenia Gravis/diagnosis , Myasthenia Gravis/epidemiology , Myasthenia Gravis/therapy
5.
Cutan Ocul Toxicol ; 32(1): 95-7, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22877081

ABSTRACT

We report a case of acute, bilateral and severe vision loss after inadvertent consumption of a large quantity of the homoeopathic medication Arnica-30. Severe vomiting which required hospitalization preceded visual symptoms. In the acute stage, pupillary responses to light were absent and fundus examination was normal. Vision loss followed a fluctuating course, with profound loss noted after 6 weeks along with bilateral optic disc pallor. Neuro-ophthalmic examination and detailed investigations were performed, including magnetic resonance imaging, electroretinography (ERG) and visual evoked potentials (VEP). Ocular coherence tomography (OCT) showed gross thinning of the retinal nerve fiber layer. While a differential diagnosis of posterior ischemic optic neuropathy was kept in mind, these findings supported a diagnosis of bilateral toxic optic neuropathy. Arnica-30 is popularly used to accelerate wound healing, including after oculoplastic surgery. While homeopathic medicines are generally considered safe due to the very low concentrations involved, Arnica-30 may be neurotoxic if consumed internally in large quantities.


Subject(s)
Arnica , Ethanol/adverse effects , Optic Neuritis/chemically induced , Plant Preparations/adverse effects , Vision Disorders/chemically induced , Alcohol-Related Disorders/drug therapy , Hematemesis/chemically induced , Humans , Male , Middle Aged , Phytotherapy/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...